|  |  |  |  |
| --- | --- | --- | --- |
| 1 | Вишневский Б.И., Яблонский П.К. Персистенция *Mycobacterium tuberculosis* — основа латентного туберкулеза (обзор литературы) // Медицинский Альянс, 2020. Т. 8, № 2. С. 14-20 | Vishnevskiy B., Yablonskiу P. The persistence of Mycobacterium tuberculosis аs the basis of latent tuberculosis (review). *Meditsinskii Alʼyans* = *Medical Alliance, 2020, Vol.8, no.2, pp.14-20* | doi: 10.36422/23076348-2020-8-2-14-20 |
| 2 | Заболотных Н.В., Виноградова Т.И., Догонадзе М.З., Витовская М.Л., Ариэль А.Б., Васильев К.А., Шурыгина А.-П.С., Бузицкая Ж.В., Стукова М.А. Эффективность применения векторной вакцины Flu/ESAT-6 в схеме комплексной терапии лекарственно-чувствительного и лекарственно-устойчивого экспериментального туберкулеза // Медицинский Альянс, 2020. Т. 8, № 4. С. 6-15 | Zabolotnykh N., T. Vinogradova T., Dogonadze M., Vitovskaya M., Ariel B., Vasilyev K., Shurygina A.-P., Buzitskaya Zh., Stukova M. Vector vaccine Flu/ESAT-6 application in the regimen of complex therapy of drug-sensitive and drug-resistant experimental tuberculosis estimation of the efficiency. *Meditsinskii Alʼyans* = *Medical Alliance, 2020, Vol.8, no.4, pp.6-15* | doi: 10.36422/23076348-2020-8-4-6-15 |
| 3 | Новицкий В.В., Стрелис А.К., Уразова О.И., Воронкова О.В., Синицына В.А., Ткаченко С.Б., Филинюк О.В., Земляная Н.А., Шилько Т.А., Есимова И.Е. Особенности поверхностного фенотипа лимфоцитов крови у больных туберкулезом//Медицинская иммунология, 2005. Т.7, № 5-6. С.587-592. | Novicky V.V., Strelis A.K., Urazova O.I., Voronkova O.V., Sinitsina V.A., Tkachenko S.B., Filiniuk O.V., Zemlianaya N.A., Shilʼko T.A., Esimova I.Ye. The featutures of surface phenotype of blood lymphocytes in the patients with tuberculosis. *Meditsinskaya Immunologiya = Medical Immunology, 2005, Vol.7, no.5-6, pp.587-592*. |  |
| 4 | Шовкун Л.А., Кудлай Д.А., Николенко Н.Ю., Кампос Е.Д., Харсеева Г.Г. Особенности формирования иммунного ответа при туберкулезе с выделением лекарственно-чувствительных и лекарственно устойчивых штаммов *M. tuberculosis* // Туберкулёз и болезни лёгких, 2019. Т. 97, № 6. С. 44-49 | Shovkun L.А., Kudlay D.А., Nikolenko N.Yu., Kampos E.D., Kharseeva G.G. Specific features of the immune response to tuberculosis when drug susceptible and drug resistant strains of *M. tuberculosis* are detected. *Tuberkylezi Bolezni Legkikh = Tuberculosis and Lung Diseases*, 2019, Vol. 97, no. 6, pp. 44-49 | doi.org/10.21292/2075-1230-2019-97-6-44-49 |
| 5 | Andersson J., Samarina A., Fink J., Rahman S., Grundstrӧm S. Impaired expression of perforin in CD8+ T cells at the site of infection in human chronic pulmonary tuberculosis. *Infection and immunity, 2007, vol.75, no.11, pp. 5210-5222*. |  | doi:10.1128/IAI.00624-07 |
| 6 | Antonioli L., Blandizzi C., Pacher P., Hasko G. Immunity, inflammation and cancer: a leading role for adenosine*. Nat. Rev. Cancer., 2013, Vol. 13, no. 12, pp. 842-857.* |  | doi: 10.1038/nrc3613 |
| 7 | Antonioli L., Csóka B., Fornai M., Colucci R., Kókai E., Drandizzi C. and Haskó Adenosine and inflammation: what's new on the horizon? Drug Discov. *Today, 2014, vol.19, no.8, pp. 1051-1068* |  | doi: 10.1016/j.drudis.2014.02.010 |
| 8 | Antonioli L., Formai M., Blandizzi C., Pacher P., Hasko G. Adenosine signaling and the immune system: when a lot could be too much. *Immunol. Lett, 2019, Vol.205, pp.9-15* |  | doi: 10.1016/j.imlet.2018.04.006. Epub 2018 Apr 24 |
| 9 | Barreira da Silva R., Laird M.E., Yatim N., Fiette L., Ingersoll M.A., Albert M.L. Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy. *Nat Immunol, 2015, Vol. 16, no. 8, pp. 850-8* |  | doi: 10.1038/ni.3201 |
| 10 | [Becerra](https://pubmed.ncbi.nlm.nih.gov/?term=Becerra%20MC%5BAuthor%5D) M.C., [Huang](https://pubmed.ncbi.nlm.nih.gov/?term=Huang%20CC%5BAuthor%5D) C.-C.,  [Lecca](https://pubmed.ncbi.nlm.nih.gov/?term=Lecca%20L%5BAuthor%5D) L., [Bayona](https://pubmed.ncbi.nlm.nih.gov/?term=Bayona%20J%5BAuthor%5D) J.,  [Contreras](https://pubmed.ncbi.nlm.nih.gov/?term=Contreras%20C%5BAuthor%5D) C., [Calderon](https://pubmed.ncbi.nlm.nih.gov/?term=Calderon%20R%5BAuthor%5D) R., [Yataco](https://pubmed.ncbi.nlm.nih.gov/?term=Yataco%20R%5BAuthor%5D) R., [Galea](https://pubmed.ncbi.nlm.nih.gov/?term=Galea%20J%5BAuthor%5D) J., [Zhang](https://pubmed.ncbi.nlm.nih.gov/?term=Zhang%20Z%5BAuthor%5D) Z., [Atwood](https://pubmed.ncbi.nlm.nih.gov/?term=Atwood%20S%5BAuthor%5D) S.,  [Cohen](https://pubmed.ncbi.nlm.nih.gov/?term=Cohen%20T%5BAuthor%5D) T., [Mitnick](https://pubmed.ncbi.nlm.nih.gov/?term=Mitnick%20CD%5BAuthor%5D) C.D., [Farmer](https://pubmed.ncbi.nlm.nih.gov/?term=Farmer%20P%5BAuthor%5D) P., [Murray](https://pubmed.ncbi.nlm.nih.gov/?term=Murray%20M%5BAuthor%5D) M. Transmissibility and potential for disease progression of drug resistant *Mycobacterium tuberculosis*: prospective cohort study |  | doi: [10.1136/bmj.l5894](https://doi.org/10.1136%2Fbmj.l5894) |
| 11 | Casrouge A., Sauer A.V., R. Barreira da Silva R., Tejera-Alhambra M., Sanchez-Ramon S., ICAReB, Cancrini C., Ingersoll M.A., Aiuti A., Albert M.L. Lymphocytes are a major source of circulating soluble dipeptidyl peptidase 4. *Clin Exp Immunol, 2018, Vol. 194, no. 2, pp. 166-179* |  | doi: 10.1111/cei.13163 |
| 12 | Costa L.R., de Souza A.K.Y., School J.N., Figueiró F., Battastini A.M.O., Dos Santos Jaques J.A., Zanoelo F.F. Biochemical characterization of adenosine deaminase (CD26; EC 3.5.4.4) activity in human lymphocyte-rich peripheral blood mononuclear cells*. Braz. J. Med. Biol. Res., 2021, Vol.54, no.8, pp.10850* |  | doi: 10.1590/1414-431X2020e10850 |
| 13 | Cox J.R., Jennings M., Lenahan C., Manion M., Courville S., Blazeck J. Rational engineering of an improved adenosine deaminase 2 enzyme for weaponizing T-cell therapies. *Immunooncol. Technol., 2023, Vol. 19, pp. 100394* |  | doi: 10.1016/j.iotech.2023.100394. |
| 14 | Chen L., Alabdullah M., Mahnke K. Adenosine, bridging chronic inflammation and tumor growth. *Front. Immunol., 2023, Vol.14, pp.1258637* |  | doi: 10.3389/fimmu.2023.1258637 |
| 15 | Dheda K., Gumbo T.,Maartens G., Dooley K.E., McNerney R., Murray M., Furin J., Nardell E.A., London L., Lessem E., Theron G., Van Helden P., Niemann S., Merker M., Dowdy D., Van Rie A., Siu G.K.H., Pasipanodya J.G., Rodrigues C., Clark T.G., Sirgel F.A., Esmail A., Lin H.-H., Atre Sachin R., Schaaf H.S., Chang K.C., Lange C., Nahid P., Udwadia Z.F., Horsburgh C.R., Churchyard G.J., Menzies D., Hesseling A.C., Nuermberger E., McIlleron H., Fennelly K.P., Goemaere E., Jaramillo E., Low Marcus, Jara C.M., Padayatchi N., Warren R.M. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. *Lancet Respir. Med*., *2017, Vol. 5, pp. 291-360* |  | doi:10.1016/s2213-2600(17)30079-6 |
| 16 | Franco R, Pacheco R, Gatell JM, Gallart T, Lluis C. Enzymatic and extraenzymatic role of adenosine deaminase 1 in T-cell-dendritic cell contacts and in alterations of the immune function. *Crit Rev Immunol., 2007, Vol.27, no.6, pp. 495-509*. |  | doi: 10.1615/critrevimmunol.v27.i6.10. |
| 17 | Hasko G., Cronstein B.N. Adenosine: an endogenous regulator of innate immunity. *Trends Immunol, 2004, Vol.25, no. 1, pp.33-39.* |  | doi: 10.1016/j.it.2003.11.003 |
| 18 | Kaufmann S.H.E., Dorhoi A. Inflammation in tuberculosis: interactions, imbalances and interventions. *Current Opinion in Immunology, 2013, Vol.25, no. 4, pp. 441-449.* |  | doi: 10.1016/j.coi.2013.05.005 |
| 19 | Kotrulev M., Gomez-Tourino I., Cordero O.J. Soluble CD26: From Suggested Biomarker for Cancer Diagnosis to Plausible Marker for Dynamic Monitoring of Immunotherapy. *Cancers, 2024, Vol.16, no.13, pp. 2427* |  | doi:10.3390/cancers16132427 |
| 20 | Lim H.-J., Jong Sun Park J.S., Cho Y.-J., Yoon H.I., Park K.U., Lee C.-T., Lee J.H. CD4+FoxP3+ T regulatory cells in drug-susceptible and multidrug-resistant tuberculosis. *Tuberculosis, 2013, Vol.93, no. 5, pp.523-8* |  | doi: 10.1016/j.tube.2013.06.001 |
| 21 | Ohta A. A metabolic immune checkpoint: adenosine in tumor microenvironment. Front. Immunol, 2016, Vol.29, no 7, pp. 109 |  | doi: 10.3389/fimmu.2016.00109 |
| 22 | Sampath P., Rajamanickam A., Thiruvengadam K., Natarajan A.P., Hissar S., Dhanapal M., Thangavelu B., Jayabal L., Ramesh P.M., Devi Ranganathan U., Babu S., Bethunaickan R. Cytokine upsurge among drug‑resistant tuberculosis endorse the signatures of hyper inflammation and disease severity. *Scientific Reports, 2023, Vol.13, pp.785* |  | doi: 10.1038/s41598-023-27895-8 |
| 23 | Tadokoro H., Hirayama A., Kudo R., Hasebe M., Yoshioka Y., Matsuzaki J.,  [Yamamoto](https://pubmed.ncbi.nlm.nih.gov/?term=%22Yamamoto%20Y%22%5BAuthor%5D) Y., [Sugimoto](https://pubmed.ncbi.nlm.nih.gov/?term=%22Sugimoto%20M%22%5BAuthor%5D) M., [Soga](https://pubmed.ncbi.nlm.nih.gov/?term=%22Soga%20T%22%5BAuthor%5D) T., [Ochiya](https://pubmed.ncbi.nlm.nih.gov/?term=%22Ochiya%20T%22%5BAuthor%5D) T.  Adenosine leakage from perforin-burst extracellular vesicles inhibits perforin secretion by cytotoxic T-lymphocytes. *PLoS ONE, 2020, Vol. 15, no. 4, pp. e0231430* |  | [doi.org/10.1371/journal.pone.0231430](https://doi.org/10.1371/journal.pone.0231430) |
| 24 | Zavialov A.V, Gracia E., Glaichenhaus N., Franco R., Zavialov A.V., Lauvau G. Human adenosine deaminase 2 induces differentiation of monocytes into macrophages and stimulates proliferation of T helper cells and macrophages. *J. of Leukocyte Biology, 2010, vol. 88, no. 2, pp. 279-290* |  | doi: 10.1189/jlb.1109764 |
| 25 | Zavialov A.V., Yu X., Spillmann D., Lauvau G., Zavialov A.V. Structural basis for the growth factor activity of human adenosine deaminase ADA2. *J Biol Chem,. 2010, Vol.285, no. 16, pp. 12367-77* |  | doi: 10.1074/jbc.M109.083527 |
| 26 | Zhang T., Tong X., Zhang S., Wang D., Wang L., Wang Q., Fan H. The roles of dipeptidyl peptidase 4 (DPP4) and DPP4 inhibitors in different lung diseases: new evidence. *Front. Pharmacol., 2021, Vol. 12, pp. 731453* |  | doi: 10.3389/fphar.2021.731453 |
| 27 | Zhulai G., Oleinik E., Shibaev, M., Ignatev K. Adenosine-metabolizing enzymes, adenosine kinase and adenosine deaminase, in cancer. *Biomolecules, 2022, Vol.12, no.3, pp. 418* |  | doi.org/10.3390/biom12030418 |